Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | BCL9 | O00512 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30373891 | 1.00 | HTR2A (0.48) | HTR2AGAABCL9CTNNB1MGLL | |
| SCHEMBL31201617 | 0.88 | HTR2A (0.49) | HTR2AGAABCL9CTNNB1MGLL | |
| SCHEMBL1872356 | 0.87 | MGLL (0.53) | HTR2AGAABCL9CTNNB1MGLL | |
| SCHEMBL389680 | 0.86 | ALDH1A1 (0.52) | HTR2AGAABCL9CTNNB1MGLL | |
| SCHEMBL21570247 | 0.86 | ALDH1A1 (0.52) | HTR2AGAABCL9CTNNB1MGLL | |
| SCHEMBL8818613 | 0.86 | ALDH1A1 (0.52) | HTR2AGAABCL9CTNNB1MGLL | |
| SCHEMBL31476222 | 0.84 | GAA (0.47) | HTR2AGAABCL9CTNNB1MGLL | |
| SCHEMBL8970953 | 0.84 | HTR2A (0.46) | HTR2AGAABCL9CTNNB1ALDH1A1 | |
| SCHEMBL30373864 | 0.84 | HTR2A (0.46) | HTR2AGAABCL9CTNNB1MGLL | |
| SCHEMBL11592383 | 0.83 | NPC1 (0.50) | GAAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | HTR2A 1950/4885GAA 1256/4885BCL9 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.